drugset
Drugs / Luseogliflozin
last change Jan 2021 re-read 9 days ago

Luseogliflozin

also known as Luseogliflozina · Luseogliflozine · TS-071 · TS-71

Small molecule

Developed for
type 2 diabetes mellitus
Investigated by
Kansai Electric Power Hospital · Medical Corporation Heishinkai OCROM Clinic

Trials 1

today NCT02500186 · not/applicable
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase not applicable1 trial
— NCT02500186 May → Dec 2015 type 2 diabetes mellitus Kansai Electric Power Hospital Completed No outcome recorded
Comparator or background therapy1 trial
Phase 4 NCT02528019 Comparator Aug 2015 → Aug 2017 — Kurume University Unknown No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2021-01-21 Taisho Pharmaceutical Co., Ltd. SGLT2阻害剤「TS-071」について小児2型糖尿病患者を対象とした国内第3相臨床試験開始のお知らせ taisho.co.jp ↗

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Luseogliflozin “luseogliflozin (2.5-5mg)” NCT02528019 ↗
1

NCT02500186 ↗
Known as Luseogliflozina ChEMBL registry synonym — accepted as the source's own label CHEMBL1093423 ↗
Known as Luseogliflozine ChEMBL registry synonym — accepted as the source's own label CHEMBL1093423 ↗
Known as TS-071 ChEMBL registry synonym — accepted as the source's own label CHEMBL1093423 ↗
Known as TS-71 ChEMBL registry synonym — accepted as the source's own label CHEMBL1093423 ↗
Action Inhibit “which inhibits glucose reabsorption from renal uriniferous tubule” NCT02500186 ↗
Modality Small molecule — CHEMBL1093423 ↗
Route Oral “Study patients orally receive luseogliflozin 2.5 mg s.i.d. before breakfast” NCT02500186 ↗